Results 71 to 80 of about 21,874 (160)

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer

Journal of Experimental & Clinical Cancer Research
Background Basket clinical trials targeting the KRASG12C-mutation in solid tumors have shown initial promise, including in orphan KRASG12C head and neck cancer (HNC).
Ofra Novoplansky, Sankar Jagadeeshan, Manu Prasad, Ksenia M. Yegodayev, Divyasree Marripati, Raghda Abu Shareb, Yariv Greenshpan, Sooraj Mathukkada, Talal Ben-Lulu, Baisali Bhattacharya, Angel Porgador, Dexin Kong, Johannes Brägelmann, J. Silvio Gutkind, Moshe Elkabets   +14 more
doaj   +1 more source

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer

Breast Cancer: Targets and Therapy, 2012
Sara A Hurvitz, Reva KakkarDepartment of Medicine, University of California, Los Angeles, CA, USAPurpose: This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents ...
Hurvitz SA, Kakkar R
doaj  

Lapatinib induces ferroptosis in osteosarcoma via the SLC1A5-GPX4 axis. [PDF]

J Bone Oncol
Miao H, Fu X, Liu B, Pan X, Han Y, Yu Z.
europepmc   +1 more source

Use of the dual tyrosine kinase inhibitor lapatinib for the treatment of vulvovaginal squamous cell carcinoma in a dog. [PDF]

J Vet Intern Med
Vardanega MJ, Longo T, Aceino A, Alexander CK.   +3 more
europepmc   +1 more source

Annexin A6 Modulates the Secretion of Pro-Inflammatory Cytokines and Exosomes via Interaction with SNAP23 in Triple-Negative Breast Cancer Cells. [PDF]

Cells
Sakwe NI, Korolkova OY, Vuong NB, Edwards AD, Black PJ, Ball DD, McIntosh AR, Thomas PL, Whalen Melvin DS, Beasley HK, Hinton AO, Ochieng J, Sakwe AM.   +12 more
europepmc   +1 more source

Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices. [PDF]

Breast Cancer (Dove Med Press)
Kullab S, Refae A, Altwairgi A, Abusanad A, Elsamany S, Abdelhafiez NA, Basulaiman B, Zahralliyali A, Alshangiti AA, Al-Mubarak M, Alwbari A, Alharbi A, Osman A, Kiwan H, Alaklabi S.   +14 more
europepmc   +1 more source

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation. [PDF]

Clin Cancer Res
Bharadwaj S, Corredor G, Al-Shakhshir H, Medina S, Almahfouz SN, Dhamdhere R, Pathak T, Fu P, Liu Y, Gandhi S, Badve S, Madabhushi A.   +11 more
europepmc   +1 more source

MUC16 promotes endometrial cancer progression and modulates sensitivity to lapatinib through the ESR1/PI3K/AKT axis. [PDF]

Transl Oncol
Yu Y, Lv S, Li G, Sun L, Su S.
europepmc   +1 more source

A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer. [PDF]

Sci Rep
Yang L, Bhattacharya A, Li Y, Peterson D, Zhang Y.   +4 more
europepmc   +1 more source

Case Report: response of HER2-positive ductal carcinoma <i>in situ</i> to osimertinib with supporting <i>in vitro</i> evidence. [PDF]

Front Oncol
Baba S, Koketsu M, Kuroda H, Suzuki M, Nishihara H, Kato Y, Kawami H, Harada O.   +7 more
europepmc   +1 more source